141 related articles for article (PubMed ID: 37876119)
1. Assessing prognostic factors of long-term survival after surgery for colorectal gastrointestinal stromal tumours.
Yang S; Maspero M; Holubar SD; Hull TL; Lightner AL; Valente MA; Gorgun E; Kalady MF; Steele SR; Liska D
Colorectal Dis; 2023 Dec; 25(12):2325-2334. PubMed ID: 37876119
[TBL] [Abstract][Full Text] [Related]
2. Rectal Gastrointestinal Stromal Tumor (GIST) in the Era of Imatinib: Organ Preservation and Improved Oncologic Outcome.
Cavnar MJ; Wang L; Balachandran VP; Antonescu CR; Tap WD; Keohan M; Singer S; Temple L; Nash GM; Weiser MR; Guillem JG; Aguilar JG; DeMatteo RP; Paty PB
Ann Surg Oncol; 2017 Dec; 24(13):3972-3980. PubMed ID: 29058144
[TBL] [Abstract][Full Text] [Related]
3. The effect of neoadjuvant imatinib therapy on outcome and survival in rectal gastrointestinal stromal tumors: A multiinstitutional study.
Yang W; Liu Q; Lin G; Zhang B; Cao H; Zhao Y; Xia L; Feng F; Xiong Z; Hu J; Ye Y; Tao K; Zhang P
J Surg Oncol; 2021 Dec; 124(7):1128-1135. PubMed ID: 34324197
[TBL] [Abstract][Full Text] [Related]
4. Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib.
Gronchi A; Bonvalot S; Poveda Velasco A; Kotasek D; Rutkowski P; Hohenberger P; Fumagalli E; Judson IR; Italiano A; Gelderblom HJ; van Coevorden F; Penel N; Kopp HG; Duffaud F; Goldstein D; Broto JM; Wardelmann E; Marréaud S; Smithers M; Le Cesne A; Zaffaroni F; Litière S; Blay JY; Casali PG
JAMA Surg; 2020 Jun; 155(6):e200397. PubMed ID: 32236507
[TBL] [Abstract][Full Text] [Related]
5. Postoperative imatinib in patients with intermediate risk gastrointestinal stromal tumor.
Wu X; Li J; Xu W; Gao J; Li Y; Shen L
Future Oncol; 2018 Jul; 14(17):1721-1729. PubMed ID: 29969914
[TBL] [Abstract][Full Text] [Related]
6. The Impact of Imatinib on Survival and Treatment Trends for Small Bowel and Colorectal Gastrointestinal Stromal Tumors.
Almaazmi H; Stem M; Lo BD; Taylor JP; Fang SH; Safar B; Efron JE; Atallah C
J Gastrointest Surg; 2020 Jan; 24(1):98-108. PubMed ID: 31388887
[TBL] [Abstract][Full Text] [Related]
7. Is 3-years duration of adjuvant imatinib mesylate treatment sufficient for patients with high-risk gastrointestinal stromal tumor? A study based on long-term follow-up.
Lin JX; Chen QF; Zheng CH; Li P; Xie JW; Wang JB; Lu J; Chen QY; Cao LL; Lin M; Tu RH; Huang CM
J Cancer Res Clin Oncol; 2017 Apr; 143(4):727-734. PubMed ID: 28083710
[TBL] [Abstract][Full Text] [Related]
8. Outcome of 1000 Patients With Gastrointestinal Stromal Tumor (GIST) Treated by Surgery in the Pre- and Post-imatinib Eras.
Cavnar MJ; Seier K; Curtin C; Balachandran VP; Coit DG; Yoon SS; Crago AM; Strong VE; Tap WD; Gönen M; Antonescu CR; Brennan MF; Singer S; DeMatteo RP
Ann Surg; 2021 Jan; 273(1):128-138. PubMed ID: 30946076
[TBL] [Abstract][Full Text] [Related]
9. [Clinical characteristics and prognosis analysis of 119 cases with giant gastrointestinal stromal tumor].
Zhang P; Zeng X; Gao J; Liu W; Shuai X; Liu K; Liu X; Cai M; Cai K; Wang G; Tao K
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1290-1295. PubMed ID: 27928802
[TBL] [Abstract][Full Text] [Related]
10. Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.
Joensuu H; Wardelmann E; Sihto H; Eriksson M; Sundby Hall K; Reichardt A; Hartmann JT; Pink D; Cameron S; Hohenberger P; Al-Batran SE; Schlemmer M; Bauer S; Nilsson B; Kallio R; Junnila J; Vehtari A; Reichardt P
JAMA Oncol; 2017 May; 3(5):602-609. PubMed ID: 28334365
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Factors After Neoadjuvant Imatinib for Newly Diagnosed Primary Gastrointestinal Stromal Tumor.
Cavnar MJ; Seier K; Gönen M; Curtin C; Balachandran VP; Tap WD; Antonescu CR; Singer S; DeMatteo RP
J Gastrointest Surg; 2021 Jul; 25(7):1828-1836. PubMed ID: 33169327
[TBL] [Abstract][Full Text] [Related]
12. Imatinib therapy after resection of high-risk gastrointestinal stromal tumors in Chinese patients: a median follow-up of 48 months.
Lei C; Zhao B; Wang Q; Ge L; Wang H
J BUON; 2018; 23(2):460-467. PubMed ID: 29745093
[TBL] [Abstract][Full Text] [Related]
13. Gastrointestinal stromal tumor of the rectum: results of surgical and multimodality therapy in the era of imatinib.
Jakob J; Mussi C; Ronellenfitsch U; Wardelmann E; Negri T; Gronchi A; Hohenberger P
Ann Surg Oncol; 2013 Feb; 20(2):586-92. PubMed ID: 22965573
[TBL] [Abstract][Full Text] [Related]
14. Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up.
Joensuu H; Eriksson M; Sundby Hall K; Reichardt A; Hermes B; Schütte J; Cameron S; Hohenberger P; Jost PJ; Al-Batran SE; Lindner LH; Bauer S; Wardelmann E; Nilsson B; Kallio R; Jaakkola P; Junnila J; Alvegård T; Reichardt P
JAMA Oncol; 2020 Aug; 6(8):1241-1246. PubMed ID: 32469385
[TBL] [Abstract][Full Text] [Related]
15. Gastric gastrointestinal stromal tumors: therapeutic strategies and long-term prognosis.
Shou C; Chen Z; Li Z; Yang W; Zhang Q; Bai H; Yu J
Scand J Gastroenterol; 2024; 59(2):239-245. PubMed ID: 37865826
[TBL] [Abstract][Full Text] [Related]
16. [Clinicopathological features and prognosis of gastrointestinal stromal tumors with
Shen YY; Li XQ; Yang LX; Fang Y; Nie MM; He ZR; Hou YY; Cao H; Wang M; Shen KT
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):804-813. PubMed ID: 34530562
[No Abstract] [Full Text] [Related]
17. Characteristics and prognosis of jejunoileal gastrointestinal stromal tumours (GISTs) in the era of imatinib: a comparative study with gastric GISTs.
Fernández JA; Ferreras D; Ruiz-Manzanera JJ; Olivares V; Ferri B; Frutos MD; Martínez J
Clin Transl Oncol; 2021 Jul; 23(7):1368-1376. PubMed ID: 33515420
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of different therapeutic modalities for rectal gastrointestinal stromal tumor: Summary of 14-year clinical experience in a single center.
Shu P; Sun XF; Fang Y; Gao XD; Hou YY; Shen KT; Qin J; Sun YH; Qin XY; Xue AW; Fu M
Int J Surg; 2020 May; 77():1-7. PubMed ID: 32173609
[TBL] [Abstract][Full Text] [Related]
19. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
Joensuu H; Eriksson M; Sundby Hall K; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Monge OR; Bono P; Kallio R; Vehtari A; Leinonen M; Alvegård T; Reichardt P
JAMA; 2012 Mar; 307(12):1265-72. PubMed ID: 22453568
[TBL] [Abstract][Full Text] [Related]
20. Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS)
Casali PG; Le Cesne A; Velasco AP; Kotasek D; Rutkowski P; Hohenberger P; Fumagalli E; Judson IR; Italiano A; Gelderblom H; Penel N; Hartmann JT; Duffaud F; Goldstein D; Martin-Broto J; Gronchi A; Wardelmann E; Marréaud S; Zalcberg JR; Litière S; Blay JY
Ann Oncol; 2021 Apr; 32(4):533-541. PubMed ID: 33482247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]